

REMARKS

1. Status of the Claims and Formal Matters

Claims 1-20 are pending in this application. Claims 9-10 and 13-20 are withdrawn from further consideration. Claims 3-4 are hereby cancelled without prejudice to pursuing these claims in a continuing application. Claims 1-2, 5-8 and 11-12 are amended. Upon entry of these amendments, claims 1-2 and 7-20 are pending with claims 1-2, 5-8, 11-12 and 14 under active consideration. Applicants respectfully request entry of the amendments and remarks made herein into the file history of the present application.

The specification is amended at page 1 to add a reference to each earlier filed application for which the benefit of an earlier filing date is claimed.

The specification is amended at paragraph [0051] to add sequence identifiers to the disclosed sequences.

The specification is amended at paragraph [0054] to add sequence identifiers to the disclosed sequences.

The specification is amended at paragraph [0057] to add sequence identifiers to the disclosed sequences.

The specification is amended at paragraph [0066] to add sequence identifiers to the disclosed sequences.

The specification is amended at paragraph [0146] to add sequence identifiers to the disclosed sequences.

The specification is amended at paragraph [0151] to correct typographical errors and add sequence identifiers to the disclosed sequences.

The specification is amended at paragraph [0157] to add sequence identifiers to the disclosed sequences.

The specification is amended at paragraph [0160] to add sequence identifiers to the disclosed sequences.

The specification is amended at Table 2 to add column "G-SEQ ID" which lists the SEQ ID NO for the top nucleic acid sequence disclosed the "BINDING-SITE" column. The specification is also amended at Table 2 to change the previous "SEQID" column label to "T-SEQID." The specification is also amended at Table to add sequence identifiers in the "T-

SEQID” column for those nucleic acid sequence disclosed in the “BINDING-SITE” column without a sequence identifier.

Claim 1 is amended to recite an “isolated” gene, support for which may be found at paragraphs [0011] and [0012]. Claim 1 is also amended to recite that the gene is an HIV gene, support for which may be found throughout the specification, notably at paragraphs [0164], [0178], [0192], [0206], [0220], [0234], [0248], [0262], [0276], [0290], [0304], [0318], [0332], [0346] and [0360]. Claim 1 is also amended to recite that the gene encodes an RNA of about 50 to about 120 nucleotides, support for which may be found at claim 1 as originally filed. Claim 1 is also amended to recite that 18 to 24 nucleotides of a first portion of the encoded RNA are at least 50% complimentary to 18 to 24 nucleotides of a second portion of the encoded RNA, support for which may be found at Table 1 and paragraph [0018]. Claim 1 is also amended to recite that at least one of the first or second portion of the RNA is at least 63% complimentary to 18 to 24 nucleotides of a human gene, support for which may be found at Table 2 and paragraph [0018].

Claim 2 is amended to recite an isolated gene that comprises a plurality of genes according to claim 1, support for which may be found throughout the specification, notably at Figure 9, paragraphs [0372] and claim 2 as originally filed.

Claim 5 is amended to recite that the RNA encoded by the DNA of claim 1 is capable of modulating expression of the human gene, support for which may be found at claim 5 as originally filed.

Claim 6 is amended to recite that the binding site sequence of the human gene is located in an untranslated region of the RNA encoded by the human gene, support for which may be found at claim 6 as originally filed.

Claim 7 is amended to recite that the binding site sequence of the human gene is located in the 3' untranslated region of the RNA encoded by the human gene, support for which may be found at paragraph [0069].

Claim 8 is amended to correct antecedent basis.

Claim 11 is amended to recite that the gene expression inhibition system comprises a vector of claim 8, support for which may be found at claim 8 as originally filed. Claim 11 is also amended to recite that the gene expression inhibition system comprises a means for inserting the

vector into a cell, support for which may be found at paragraph [0026] and claim 8 as originally filed.

Claim 12 is amended to correct antecedent basis.

2. Patentability Objections – Sequence Rules

At page 2 of the Office Action, the Examiner objects to the disclosure for allegedly failing to comply with the requirements set forth in 37 C.F.R. §§ 1.821-1.825 (the “Sequence Rules”). The specification has been amended to provide sequence identifiers for recited sequences, as set forth above. The Sequence Listing has been amended to correctly identify the source organism for the target gene binding site sequences shown in Table 2 as “human,” support for which may be found throughout the specification as originally filed including Table 2. Applicants submit herewith a replacement Sequence Listing in accordance with 37 C.F.R. §§ 1.821-1.825. Accordingly, Applicants respectfully request that the objection for failing to comply with the Sequence Rules be withdrawn.

3. Election

At pages 2-4 of the Office Action, the Examiner requires restriction to one of the following inventions under 35 U.S.C. 121:

- I. Claims 1-8, 11-12 and 14, drawn to a bioinformatically detectable novel viral gene, a probe comprising said novel gene, a vector comprising said novel gene, a kit comprising said vector and a vector inserter and a kit comprising said probe and a gene expression detector.
- II. Claims 9 and 10, drawn to a method of inhibiting translation of at least one gene comprising introducing the vector of claim 10 into a cell.
- III. Claim 13, drawn to a method of detecting gene expression using a DNA probe that comprises a bioinformatically detectable novel gene.
- IV. Claim 16, drawn to an antiviral substance capable of neutralizing RNA comprising complementarily binding the RNA.
- V. Claim 17, drawn to an antiviral substance capable of neutralizing RNA comprising immunologically neutralizing RNA.
- VI. Claim 19, drawn to a method of anti-viral treatment comprising neutralizing RNA comprising synthesizing, transfecting and complementarily binding RNA.

VII. Claim 20, drawn to a method of anti-viral treatment comprising neutralizing RNA comprising immunologically neutralizing RNA.

Applicants elect without traverse Group I, claims 1-8, 11-12 and 14, drawn to bioinformatically detectable novel viral gene, a probe comprising said novel gene, a vector comprising said novel gene, a kit comprising said vector and a vector inserter and a kit comprising said probe and a gene expression detector.

4. Conclusion


Applicant respectfully submits that the instant application is in good and proper order for allowance and early notification to this effect is solicited. If, in the opinion of the Examiner, a telephone conference would expedite prosecution of the instant application, the Examiner is encouraged to call the undersigned at the number listed below.

Respectfully submitted,

HOWREY SIMON ARNOLD & WHITE, LLP


Dated: July 20, 2005

By:



Teddy C. Scott, Jr., Ph.D.
Registration No.: 53,573
Customer No.: 22930

HOWREY LLP
321 N. Clark Street, Suite 3400
Chicago, IL 60661
(312) 595-1239 (main)
(312) 846-5621 (direct)
(312) 595-2250 (fax)



APPENDIX A

For the convenience of the Examiner, Applicant presents herewith a copy of the claims that will be pending upon entry of the present amendments.

1. (currently amended) An isolated HIV gene encoding an RNA of about 50 to about 120 nucleotides, wherein a first portion of the RNA of 18 to 24 nucleotides is at least 50% complementary to a second portion of the RNA sequence of 18 to 24 nucleotides, and wherein at least one of the first or second portion of the RNA is at least 63% complementary to a binding site sequence of 18 to 24 nucleotides of a human gene.
2. (currently amended) An isolated HIV gene comprising a plurality of genes according to claim 1.
3. (canceled)
4. (canceled)
5. (currently amended) The gene according to claim 1 wherein said encoded RNA is capable of modulating expression of said human gene.
6. (currently amended) The gene according to claim 1 wherein said binding site sequence is located in an untranslated region of RNA encoded by said human gene.
7. (currently amended) The gene according to claim 6 wherein the binding site sequence is located in the 3'untranslated region of the RNA encoded by said human gene.
8. (currently amended) A vector comprising the gene of claim 1.
9. (withdrawn) A method of selectively inhibiting translation of at least one gene, comprising introducing the vector of claim 8 into a cell.
10. (withdrawn) A method according to claim 9 and wherein said introducing comprises utilizing RNAi pathway.
11. (currently amended) A gene expression inhibition system comprising the vector of claim 8 and a means for inserting said vector into a cell.
12. (currently amended) A probe comprising the gene of claim 1.
13. (withdrawn) A method of selectively detecting expression of at least one gene, comprising using the probe of claim 12.

14. (original) A gene expression detection system comprising: the probe of claim 12; and a gene expression detector functional to selectively detect expression of at least one gene.

15. (withdrawn) An anti-viral substance capable of neutralizing said RNA of claim 1.

16. (withdrawn) A substance according to claim 15 and wherein said neutralizing comprises complementarily binding said RNA.

17. (withdrawn) A substance according to claim 15 and wherein said neutralizing comprises immunologically neutralizing.

18. (withdrawn) A method for anti-viral treatment comprising neutralizing said RNA of claim 1.

19. (withdrawn) A method according to claim 18 and wherein said neutralizing comprises: synthesizing a complementary nucleic acid molecule, a nucleic sequence of which complementary nucleic acid molecule is a partial inversed-reversed sequence of said RNA; and transfecting host cells with said complementary nucleic acid molecule, thereby complementarily binding said RNA.

20. (withdrawn) A method according to claim 18 and wherein said neutralizing comprises immunologically neutralizing.

aggacatagg catgggcaag gacttcatgt ccaaaacacc aaaagcaatg gcaacaaaag	1080
acaaaattga caaatgggat ctaattaaac taaagagctt ctgcacagca aaagaaacta	1140
ccatcagagt gaacaggcaa cctacaaaat gggagaaaat tttcgcaacc tactcatctg	1200
acaaagggct aatatccaga atctacaatg aactcaaaca aatttacaaa aaaaaaaaaa	1260
aa	1262

<210> 417
 <211> 1445
 <212> DNA
 <213> Human

<400> 417	
actcctatca acagtgtaaa agcattcctg tttctccata atcttgccag catcttttca	60
tttttttgaa ttatagccat tctgactgtt gtgagatggg gtctcattgt ggttttgatt	120
tgcattttctc agatgatcag tgatgttgaa gtttttttgt ttgttggtctg catgtatgcc	180
ttcttttgaa aagtgtctgt ttgtgtcctt tgaccacttt ctaatggggg tgagtttttt	240
tttcttgtaa atttgtttta gttccttgta gatgctggat attagacctt tgtcagatgg	300
atagagtgca aaaattttct cccattctgt aggttgctcg tttactctgt tgataggttc	360
ttaatgctgt gcagaagctc tttagttaa ttagatccca tttgtcaatt ttggcttttg	420
ttgcaattgc ttttggcatc ttctgcatga aatctttgcc cttgcctgtg tcctgaatgg	480
cattgcctag gttttcttcc aggattttta tagttttggg ttgtagattt aagtctttta	540
tccatcttga gttaactttt gtatatgggt taaggaaggg gcccgtttca atttgctgca	600
aatggctagc cagttctccc agcaccattt attaaatagg gaatcttttc cccattgctt	660
ccttttgtca ggtttgtcaa agatcacatg gttgtaggtg tgtgggtctta tttctggggt	720
ctctattctg ttccattggg ctatgggccg gttctgtacc accactatgc tgttttgggt	780
accatagtct tgtagaatgt ttgaagctgg gtagcatgat gcctctagct ttgctcttct	840
tgctaagaaa tgtcttggct atttgggctc ttttttgggt ccatatgaat tttaaaatag	900
ctttttctag gtctgtaaaag aatgtgaata gtagtttaat gggcctagca tttaatttac	960
agattgcctt gggcagtggt gtcattttca cgatattgat ccttcctgtc tgtgagcata	1020
tgtttttcca tttgtttgtg tcactctctga tttctttgaa taatggttta tagttatcct	1080
tgaaaagggtc cttcactttt cttgttagct gtattcctag atattatact cttcttgtgg	1140
caattgtgaa tgggagttta ttcattgagt ttctctcggc ttgcctgttg ttggtgtata	1200

ggaatgctag tgacttttgc acattgattt tgtatcctga gactttgttg aagttgctta	1260
tcagctaaga agtttttgag ctgagatgat ggagttttct agatatagga tcatatcatc	1320
tgcaaacaaa gatagtttga cttcctgtct tcctatttga atagcttttc tttctttctc	1380
ttgcctgatt gccttgggtga gaattttctaa tactgtgttg aataggagtg gtgagctcgt	1440
gccaa	1445

<210> 418.
 <211> 22
 <212> DNA
 <213> Human

<400> 418	
tgaggtagta agttgtattg tt	22

<210> 419
 <211> 24
 <212> DNA
 <213> Human

<400> 419	
aattgcttga acccaggaag tgga	24

<210> 420
 <211> 60
 <212> DNA
 <213> Human

<400> 420	
agccaaaaga acaaagctgg aggcatacaca ctacctgact tcaaacttta ctacaaggct	60

<210> 421
 <211> 58
 <212> DNA
 <213> Human

<400> 421	
tcagagtga caggcaacct acaaaatggg agaaaatttt cgcaacctac tcatctga	58

<210> 422
 <211> 130
 <212> DNA
 <213> Human

<400> 422	
ttccatttgt ttgtgtcatc tctgatttct ttgaataatg gtttatagtt atccttgaaa	60
aggtccttca cttttcttgt tagctgtatt cctagatatt atactcttct tgtggcaatt	120

gtgaatggga 130

<210> 423
<211> 22
<212> DNA
<213> Human immunodeficiency virus 1

<400> 423
gagtcgcgaga tcttcagacc tg 22

<210> 424
<211> 24
<212> DNA
<213> Human immunodeficiency virus 1

<400> 424
tgagtcgcgag atcttcagac ctgg 24

<210> 425
<211> 18
<212> DNA
<213> Human immunodeficiency virus 1

<400> 425
tgagtcgcgag atcttcag 18

<210> 426
<211> 23
<212> DNA
<213> Human immunodeficiency virus 1

<400> 426
tgagtcgcgag atctatagac ctg 23

<210> 427
<211> 19
<212> DNA
<213> Human immunodeficiency virus 1

<400> 427
ttttatagac atcactatg 19

<210> 428
<211> 18
<212> DNA
<213> Human immunodeficiency virus 1

<400> 428
tttatagaca tcactatg 18

<210>	429	
<211>	21	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	429	
	gatacagagg tacataatgt t	21
<210>	430	
<211>	23	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	430	
	atgatacaga ggtacataat gtt	23
<210>	431	
<211>	23	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	431	
	tatgatacag aggtacataa tgt	23
<210>	432	
<211>	22	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	432	
	tgatacagag gtacataatg tt	22
<210>	433	
<211>	18	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	433	
	ttaagtgttt caattgtg	18
<210>	434	
<211>	18	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	434	
	taagtgtttc aattgtgg	18
<210>	435	
<211>	19	

<212> DNA
 <213> Human immunodeficiency virus 1

 <400> 435
 ttaagtgttt caattgtgg 19

 <210> 436
 <211> 15
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 436
 gtgttttcaat tgtgg 15

 <210> 437
 <211> 21
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 437
 cagaagaaaa aataaaagca t 21

 <210> 438
 <211> 22
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 438
 tgacagaaga aaaaataaaa gc 22

 <210> 439
 <211> 20
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 439
 tgacagaaga aaaaataaaa 20

 <210> 440
 <211> 19
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 440
 tgacagaaga aaaaataaaa 19

 <210> 441
 <211> 21
 <212> DNA
 <213> Human immunodeficiency virus 1

<400> 441
gacagaagaa aaaataaaag c 21

<210> 442
<211> 24
<212> DNA
<213> Human immunodeficiency virus 1

<400> 442
tgacagaaga aaaaataaaa gcat 24

<210> 443
<211> 23
<212> DNA
<213> Human immunodeficiency virus 1

<400> 443
tgacagaaga aaaaataaaa gca 23

<210> 444
<211> 23
<212> DNA
<213> Human immunodeficiency virus 1

<400> 444
gacagaagaa aaaataaaag cat 23

<210> 445
<211> 22
<212> DNA
<213> Human immunodeficiency virus 1

<400> 445
acagaagaaa aaataaaagc at 22

<210> 446
<211> 18
<212> DNA
<213> Human immunodeficiency virus 1

<400> 446
tgacagaaga aaaaataa 18

<210> 447
<211> 20
<212> DNA
<213> Human immunodeficiency virus 1

<400> 447
agaagaaaaa ataaaagcat 20

<210>	448	
<211>	18	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	448	
	gaagaaaaaa taaaagca	18
<210>	449	
<211>	18	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	449	
	agaagaaaaa ataaaagc	18
<210>	450	
<211>	21	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	450	
	tgacagaaga aaaaataaaa g	21
<210>	451	
<211>	19	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	451	
	gaagaaaaaa taaaagcat	19
<210>	452	
<211>	21	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	452	
	acagaagaaa aaataaaagc a	21
<210>	453	
<211>	20	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	453	
	ttgtgtgcat caaaggatag	20
<210>	454	
<211>	24	

<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	454	
	tattgtgtgc atcaaaggat agag	24
<210>	455	
<211>	20	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	455	
	tgtgtgcatc aaaggataga	20
<210>	456	
<211>	18	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	456	
	tattgtgtgc atcaaagg	18
<210>	457	
<211>	22	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	457	
	ttgtgtgcat caaaggatag ag	22
<210>	458	
<211>	19	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	458	
	tgtgtgcatc aaaggatag	19
<210>	459	
<211>	19	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	459	
	tttttgctgt actttctat	19
<210>	460	
<211>	18	
<212>	DNA	
<213>	Human immunodeficiency virus 1	

<400> 460
tagtttttgc tgtacttt 18

<210> 461
<211> 22
<212> DNA
<213> Human immunodeficiency virus 1

<400> 461
gtttttgctg tactttctat ag 22

<210> 462
<211> 24
<212> DNA
<213> Human immunodeficiency virus 1

<400> 462
tagtttttgc tgtactttct atag 24

<210> 463
<211> 18
<212> DNA
<213> Human immunodeficiency virus 1

<400> 463
agatgggtgg caagtgg 18

<210> 464
<211> 19
<212> DNA
<213> Human immunodeficiency virus 1

<400> 464
aagatgggtg gcaagtgg 19

<210> 465
<211> 17
<212> DNA
<213> Human immunodeficiency virus 1

<400> 465
gatgggtggc aagtgg 17

<210> 466
<211> 20
<212> DNA
<213> Human immunodeficiency virus 1

<400> 466
taagatgggt ggcaagtgg 20

<210>	467	
<211>	18	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	467	
	taagatgggt ggcaagtg	18
<210>	468	
<211>	15	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	468	
	tgggtggcaa gtggt	15
<210>	469	
<211>	20	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	469	
	cagactcatc aagcttctct	20
<210>	470	
<211>	18	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	470	
	cagactcatc aagcttct	18
<210>	471	
<211>	19	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	471	
	agactcatca agcttctct	19
<210>	472	
<211>	18	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	472	
	gactcatcaa gcttctct	18
<210>	473	
<211>	16	

<212> DNA
 <213> Human immunodeficiency virus 1

 <400> 473
 cagactcatc aagctt 16

 <210> 474
 <211> 16
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 474
 ctcacatcaagc ttctct 16

 <210> 475
 <211> 16
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 475
 gactcatcaa gcttct 16

 <210> 476
 <211> 17
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 476
 agactcatca agcttct 17

 <210> 477
 <211> 18
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 477
 tccaaaatgc gaacccag 18

 <210> 478
 <211> 17
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 478
 tgccaaccca gattgta 17

 <210> 479
 <211> 21
 <212> DNA
 <213> Human immunodeficiency virus 1

<400> 479
caaaatgcga acccagattg t 21

<210> 480
<211> 18
<212> DNA
<213> Human immunodeficiency virus 1

<400> 480
atgcgaaccc agattgta 18

<210> 481
<211> 22
<212> DNA
<213> Human immunodeficiency virus 1

<400> 481
tccaaaatgc gaaccagat tg 22

<210> 482
<211> 23
<212> DNA
<213> Human immunodeficiency virus 1

<400> 482
tccaaaatgc gaaccagat tgt 23

<210> 483
<211> 20
<212> DNA
<213> Human immunodeficiency virus 1

<400> 483
aaaatgcgaa cccagattgt 20

<210> 484
<211> 22
<212> DNA
<213> Human immunodeficiency virus 1

<400> 484
caaaatgcga acccagattg ta 22

<210> 485
<211> 16
<212> DNA
<213> Human immunodeficiency virus 1

<400> 485
tccaaaatgc gaaccc 16

<210>	486	
<211>	23	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	486	
	tctctgggta gaccagatct gag	23
<210>	487	
<211>	22	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	487	
	tctgggtaga ccagatctga gc	22
<210>	488	
<211>	24	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	488	
	tctctgggta gaccagatct gagg	24
<210>	489	
<211>	21	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	489	
	ctggtagac cagatctgag c	21
<210>	490	
<211>	20	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	490	
	ctctggtag accagatctg	20
<210>	491	
<211>	21	
<212>	DNA	
<213>	Human immunodeficiency virus 1	
<400>	491	
	tctggtaga ccagatctga g	21
<210>	492	
<211>	17	

<212> DNA
 <213> Human immunodeficiency virus 1

 <400> 492
 ttgcacttta aattttc 17

 <210> 493
 <211> 24
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 493
 ttggttgacac tttaaatttt ccca 24

 <210> 494
 <211> 21
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 494
 ttggttgacac tttaaatttt c 21

 <210> 495
 <211> 23
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 495
 ttggttgacac tttaaatttt ccc 23

 <210> 496
 <211> 20
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 496
 ttggttgacac tttaaatttt 20

 <210> 497
 <211> 22
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 497
 ggcaacgacc cctcgtcaca at 22

 <210> 498
 <211> 17
 <212> DNA
 <213> Human immunodeficiency virus 1

<400> 498
tggcaacgac ccctcgt 17

<210> 499
<211> 24
<212> DNA
<213> Human immunodeficiency virus 1

<400> 499
tggcaacgac ccctcgtcac aata 24

<210> 500
<211> 20
<212> DNA
<213> Human immunodeficiency virus 1

<400> 500
gtgcagaaca tccaggggca 20

<210> 501
<211> 19
<212> DNA
<213> Human immunodeficiency virus 1

<400> 501
tagtgcagaa catccaggg 19

<210> 502
<211> 22
<212> DNA
<213> Human immunodeficiency virus 1

<400> 502
tagtgcagaa catccagggg ca 22

<210> 503
<211> 19
<212> DNA
<213> Human immunodeficiency virus 1

<400> 503
atagtgcaga acatccagg 19

<210> 504
<211> 18
<212> DNA
<213> Human immunodeficiency virus 1

<400> 504
tatagtgcag aacatcca 18

<210> 505
<211> 21
<212> DNA
<213> Human immunodeficiency virus 1

<400> 505
agtcgagaac atccaggggc a 21

<210> 506
<211> 19
<212> DNA
<213> Human immunodeficiency virus 1

<400> 506
gtgcagaaca tccaggggc 19

<210> 507
<211> 21
<212> DNA
<213> Human immunodeficiency virus 1

<400> 507
tagtgcagaa catccagggg c 21

<210> 508
<211> 23
<212> DNA
<213> Human immunodeficiency virus 1

<400> 508
tatagtgcag aacatccagg ggc 23

<210> 509
<211> 19
<212> DNA
<213> Human immunodeficiency virus 1

<400> 509
agtcgagaac atccagggg 19

<210> 510
<211> 20
<212> DNA
<213> Human immunodeficiency virus 1

<400> 510
tagtgcagaa catccagggg 20

<210> 511
<211> 20

<212> DNA
 <213> Human immunodeficiency virus 1

 <400> 511
 agtgcagaac atccaggggc 20

 <210> 512
 <211> 24
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 512
 tatagtgcag aacatccagg ggca 24

 <210> 513
 <211> 23
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 513
 gccttaggca tctcctatgg cag 23

 <210> 514
 <211> 23
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 514
 agccttaggc atctcctatg gca 23

 <210> 515
 <211> 16
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 515
 agccttaggc atctcc 16

 <210> 516
 <211> 20
 <212> DNA
 <213> Human immunodeficiency virus 1

 <400> 516
 gccttaggca tctcctatgg 20

 <210> 517
 <211> 22
 <212> DNA
 <213> Human immunodeficiency virus 1

<400> 517
agccttaggc atctcctatg gc 22

<210> 518
<211> 24
<212> DNA
<213> Human immunodeficiency virus 1

<400> 518
agccttaggc atctcctatg gcag 24

<210> 519
<211> 19
<212> DNA
<213> Human immunodeficiency virus 1

<400> 519
gccttaggca tctcctatg 19

<210> 520
<211> 21
<212> DNA
<213> Human immunodeficiency virus 1

<400> 520
cttaggcac tcctatggc g 21

<210> 521
<211> 21
<212> DNA
<213> Human immunodeficiency virus 1

<400> 521
gccttaggca tctcctatgg c 21

<210> 522
<211> 18
<212> DNA
<213> Human immunodeficiency virus 1

<400> 522
cttaggcac tcctatgg 18

<210> 523
<211> 21
<212> DNA
<213> Human immunodeficiency virus 1

<220>
<221> misc_feature

<222> (18)..(20)

<223> n=i

<400> 523

tgcgaaacca gattgtannn t

21

<210> 524

<211> 26

<212> DNA

<213> Human

<220>

<221> misc_feature

<222> (23)..(25)

<223> n=i

<400> 524

accttatact gtagtccaac atnnna

26